Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
about
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.Will drug resistance against dolutegravir in initial therapy ever occur?Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.HIV-1 resistance to dolutegravir: update and new insights.Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.HIV drug resistance against strand transfer integrase inhibitorsHIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
P2860
Q35083423-F7E34D6E-78B6-4269-BE61-7B43AA87588FQ36284159-32E617A4-79C1-43B9-ABBB-CC4EE5EB7875Q36977388-FA3CC092-7D23-48DC-B143-C566417EFEDFQ38478832-F3D82E34-5375-42DF-980F-B076DDE51466Q38570500-03511A96-7879-4661-AA38-3CADC3D955A0Q38601891-C16EC760-D695-40D0-AEE7-367BBE082519Q38849946-DC53FC80-14EE-4A9E-BDFA-CB853E2A38B0Q38915885-A7DDA7D6-5E90-4B65-8B72-49BB5FB701F8Q38924027-3C42E587-7F4F-4547-B32F-77A160984CE1Q39352571-E981DC0F-DA67-4E76-A6A7-20B255921AC4Q40215127-B4B059DF-9522-42EA-AC2B-6AC464623429Q40655736-94F632A6-8112-4C52-A48B-F26772EA65E7Q41012861-0957B3D6-C463-4905-ABD6-0CC7B8A2E4FEQ47301806-0808B369-209B-4DFF-869B-CB66F43C6C87
P2860
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Evolution of a novel pathway l ...... nd multiclass drug resistance.
@en
type
label
Evolution of a novel pathway l ...... nd multiclass drug resistance.
@en
prefLabel
Evolution of a novel pathway l ...... nd multiclass drug resistance.
@en
P2093
P2860
P356
P1476
Evolution of a novel pathway l ...... nd multiclass drug resistance.
@en
P2093
Bluma Brenner
Christos Petropoulos
Daniela Moisi
Isabelle Hardy
Mark A Wainberg
Michel Roger
Peter Quashie
Réjean Thomas
P2860
P304
P356
10.1093/JAC/DKU387
P407
P577
2014-10-03T00:00:00Z